{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:47:45Z","timestamp":1791294465327,"version":"4.1.0"},"reference-count":237,"publisher":"Elsevier","isbn-type":[{"value":"9780128022658","type":"print"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1016\/bs.acc.2014.12.002","type":"book-chapter","created":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T15:03:00Z","timestamp":1423321380000},"page":"47-89","source":"Crossref","is-referenced-by-count":40,"title":["Circulating Biomarkers in Malignant Melanoma"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acc.2014.12.002_bb0005","doi-asserted-by":"crossref","first-page":"599.e1","DOI":"10.1016\/j.jaad.2014.05.046","article-title":"Screening, early detection, education, and trends for melanoma: current status (2007-2013) and future directions: part I. Epidemiology, high-risk groups, clinical strategies, and diagnostic technology","volume":"71","author":"Mayer","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0010","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","article-title":"The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia","volume":"9","author":"Bastian","year":"2014","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0020","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0025","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0035","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0040","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0045","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0050","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2014.12.002_bb0055","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0060","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0065","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-genom-091212-153429","article-title":"The genetics of melanoma: recent advances","volume":"14","author":"Hill","year":"2013","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/bs.acc.2014.12.002_bb0075","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0080","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0085","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jamcollsurg.2004.10.032","article-title":"Detection of B-RAF and N-RAS mutations in human melanoma","volume":"200","author":"Goydos","year":"2005","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/bs.acc.2014.12.002_bb0090","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond","volume":"14","author":"Holderfield","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0095","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2014.12.002_bb0100","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1083\/jcb.200505059","article-title":"Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation","volume":"170","author":"Wellbrock","year":"2005","journal-title":"J. Cell Biol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0105","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1128\/MCB.24.7.2923-2931.2004","article-title":"The Brn-2 transcription factor links activated BRAF to melanoma proliferation","volume":"24","author":"Goodall","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0110","doi-asserted-by":"crossref","first-page":"33168","DOI":"10.1074\/jbc.M405102200","article-title":"Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling","volume":"279","author":"Huntington","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2014.12.002_bb0115","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2014.12.002_bb0120","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1158\/0008-5472.CAN-04-1399","article-title":"Deregulated Akt3 activity promotes development of malignant melanoma","volume":"64","author":"Stahl","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0125","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1126\/science.7809631","article-title":"Inhibition of ras-induced proliferation and cellular transformation by p16INK4","volume":"267","author":"Serrano","year":"1995","journal-title":"Science"},{"key":"10.1016\/bs.acc.2014.12.002_bb0130","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nature05985","article-title":"The common biology of cancer and ageing","volume":"448","author":"Finkel","year":"2007","journal-title":"Nature"},{"key":"10.1016\/bs.acc.2014.12.002_bb0135","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/archderm.137.11.1493","article-title":"Genetic epidemiology of cutaneous melanoma: a global perspective","volume":"137","author":"Goldstein","year":"2001","journal-title":"Arch. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0140","doi-asserted-by":"crossref","first-page":"9818","DOI":"10.1158\/0008-5472.CAN-06-0494","article-title":"High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL","volume":"66","author":"Goldstein","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0145","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1038\/sj.onc.1206445","article-title":"Genetics of melanoma predisposition","volume":"22","author":"Hayward","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/bs.acc.2014.12.002_bb0150","first-page":"3200","article-title":"Cyclin D1 is a candidate oncogene in cutaneous melanoma","volume":"62","author":"Sauter","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejcb.2013.12.002","article-title":"Oncogenes in melanoma: an update","volume":"93","author":"Kunz","year":"2014","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0160","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/0140-6736(91)92100-G","article-title":"Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction","volume":"338","author":"Smith","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2014.12.002_bb0165","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.1158\/1078-0432.CCR-05-1769","article-title":"Circulating tumor cells versus imaging\u2014predicting overall survival in metastatic breast cancer","volume":"12","author":"Budd","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0170","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0175","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","article-title":"Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0180","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1373\/clinchem.2006.081828","article-title":"Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers","volume":"53","author":"Xi","year":"2007","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2014.12.002_bb0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1373\/clinchem.2012.194258","article-title":"Circulating tumor cells: liquid biopsy of cancer","volume":"59","author":"Alix-Panabieres","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2014.12.002_bb0190","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1006\/scbi.2001.0388","article-title":"Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells","volume":"11","author":"Pantel","year":"2001","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0195","doi-asserted-by":"crossref","first-page":"e66731","DOI":"10.1371\/journal.pone.0066731","article-title":"A melanoma brain metastasis with a donor-patient hybrid genome following bone marrow transplantation: first evidence for fusion in human cancer","volume":"8","author":"Lazova","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2014.12.002_bb0200","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1126\/science.1244270","article-title":"Cancer. Fusion for moving","volume":"342","author":"Clawson","year":"2013","journal-title":"Science"},{"key":"10.1016\/bs.acc.2014.12.002_bb0205","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.critrevonc.2014.01.007","article-title":"Detection methods of circulating tumor cells in cutaneous melanoma: a systematic review","volume":"91","author":"Rodic","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0210","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bjc.2012.12","article-title":"Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level","volume":"106","author":"Sakaizawa","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0215","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1111\/j.1610-0387.2008.06711.x","article-title":"Short German guidelines: malignant melanoma","volume":"6","author":"Garbe","year":"2008","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"10.1016\/bs.acc.2014.12.002_bb0220","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-3-642-59537-0_6","article-title":"Rapid enrichment and detection of melanoma cells from peripheral blood mononuclear cells by a new assay combining immunomagnetic cell sorting and immunocytochemical staining","volume":"158","author":"Siewert","year":"2001","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0225","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/CMR.0000000000000025","article-title":"Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma","volume":"24","author":"Khoja","year":"2014","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0230","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/(SICI)1098-2825(1999)13:5<229::AID-JCLA7>3.0.CO;2-Y","article-title":"Detection of circulating melanoma cells by immunomagnetic cell sorting","volume":"13","author":"Benez","year":"1999","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/bs.acc.2014.12.002_bb0235","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1038\/jid.2010.141","article-title":"Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma","volume":"130","author":"De Giorgi","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0240","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1479-5876-9-70","article-title":"Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients","volume":"9","author":"Liu","year":"2011","journal-title":"J. Transl. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0245","first-page":"755","article-title":"Circulating melanoma cells and survival in metastatic melanoma","volume":"38","author":"Rao","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0250","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1158\/0008-5472.CAN-05-4198","article-title":"Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients","volume":"66","author":"Koyanagi","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0255","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/jid.2010.285","article-title":"Expression of the stem cell markers nestin and CD133 on circulating melanoma cells","volume":"131","author":"Fusi","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0260","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/jid.2009.195","article-title":"Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma","volume":"130","author":"Goto","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0265","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1054\/bjoc.1998.0887","article-title":"Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors","volume":"82","author":"Proebstle","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0270","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00008390-200208000-00002","article-title":"Magnetic bead RT-PCR: establishment of a new method for detecting circulating melanoma cells","volume":"12","author":"Georgieva","year":"2002","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0275","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/CMR.0b013e32833906b6","article-title":"Prognostic value of microphthalmia-associated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma","volume":"20","author":"Samija","year":"2010","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0280","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bjd.12057","article-title":"Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression","volume":"168","author":"Reid","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0285","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jdermsci.2003.09.003","article-title":"Detection of tyrosinase and tyrosinase-related protein 1 sequences from peripheral blood of melanoma patients using reverse transcription-polymerase chain reaction","volume":"33","author":"Jin","year":"2003","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/bs.acc.2014.12.002_bb0290","doi-asserted-by":"crossref","first-page":"e41052","DOI":"10.1371\/journal.pone.0041052","article-title":"Circulating tumor cells in melanoma patients","volume":"7","author":"Clawson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2014.12.002_bb0295","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/sj.bjc.6601197","article-title":"Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients","volume":"89","author":"Osella-Abate","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0300","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2133.2010.09779.x","article-title":"Expression of the stem cell marker nestin in peripheral blood of patients with melanoma","volume":"163","author":"Fusi","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0305","first-page":"1497","article-title":"Changes in the presence of multiplemarkers of circulating melanoma cells correlate with clinical outcome in patients with melanoma","volume":"9","author":"Reynolds","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0310","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0002-9440(10)64706-2","article-title":"Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells","volume":"156","author":"Vona","year":"2000","journal-title":"Am. J. Pathol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0315","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/archdermatol.2010.264","article-title":"Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis","volume":"146","author":"De Giorgi","year":"2010","journal-title":"Arch. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0320","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/srep01259","article-title":"Isolation and retrieval of circulating tumor cells using centrifugal forces","volume":"3","author":"Hou","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.acc.2014.12.002_bb0325","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1039\/C3LC50617G","article-title":"Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells","volume":"14","author":"Warkiani","year":"2014","journal-title":"Lab Chip"},{"key":"10.1016\/bs.acc.2014.12.002_bb0330","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.18632\/oncotarget.1683","article-title":"Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma","volume":"5","author":"Joshi","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/bs.acc.2014.12.002_bb0335","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/1479-5876-10-192","article-title":"Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells","volume":"10","author":"Freeman","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0340","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/labinvest.2013.116","article-title":"Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?","volume":"94","author":"Lee","year":"2014","journal-title":"Lab. Invest."},{"key":"10.1016\/bs.acc.2014.12.002_bb0345","first-page":"127","article-title":"Circulating tumor cells in melanoma: a review of the literature and description of a novel technique","volume":"21","author":"Steen","year":"2008","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"key":"10.1016\/bs.acc.2014.12.002_bb0350","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.2005.03.2342","article-title":"Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma","volume":"24","author":"Scoggins","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0355","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2002.08.009","article-title":"Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon","volume":"20","author":"Mellado","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0360","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.jid.5700139","article-title":"Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma","volume":"126","author":"Schmidt","year":"2006","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0365","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/CMR.0b013e3280a60878","article-title":"Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma","volume":"17","author":"Visus","year":"2007","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0370","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.2005.04.098","article-title":"Molecular staging in stage II and III melanoma patients and its effect on long-term survival","volume":"23","author":"Voit","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0375","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1016\/j.ejca.2009.09.004","article-title":"Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)","volume":"45","author":"Fusi","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0380","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1155\/2006\/462065","article-title":"Prognostic value of RT-PCR tyrosinase detection in peripheral blood of melanoma patients","volume":"22","author":"Carrillo","year":"2006","journal-title":"Dis. Markers"},{"key":"10.1016\/bs.acc.2014.12.002_bb0385","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2011.40.0887","article-title":"Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial","volume":"30","author":"Hoshimoto","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0390","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/CMR.0b013e328054c667","article-title":"Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients","volume":"17","author":"Quaglino","year":"2007","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0395","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/cncr.11250","article-title":"Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase\/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients","volume":"97","author":"Garbe","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0400","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1083\/jcb.97.2.480","article-title":"Regulation of tyrosinase in human melanocytes grown in culture","volume":"97","author":"Halaban","year":"1983","journal-title":"J. Cell Biol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0405","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/bjc.1995.293","article-title":"The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction","volume":"72","author":"Foss","year":"1995","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0410","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000328283","article-title":"Prognostic relevance of circulating tumor cells in metastatic uveal melanoma","volume":"80","author":"Schuster","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/bs.acc.2014.12.002_bb0415","first-page":"1371","article-title":"Melanoma-associated antigens as messenger RNA detection markers for melanoma","volume":"57","author":"Sarantou","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0420","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1078-0432.CCR-0610-3","article-title":"Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction","volume":"10","author":"Keilholz","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0425","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0959-8049(97)10105-8","article-title":"Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group","volume":"34","author":"Keilholz","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0430","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00008390-200004000-00003","article-title":"The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival","volume":"10","author":"Aubin","year":"2000","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0435","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/jid.2012.468","article-title":"Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma","volume":"133","author":"Khoja","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0440","first-page":"325","article-title":"A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma","volume":"137","author":"Tsao","year":"2001","journal-title":"Arch. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0445","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1373\/49.9.1429","article-title":"The sporadic nature of shedding cells in blood: multiple RNA diagnostic testing and prognostication of cancer progression","volume":"49","author":"Wong","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2014.12.002_bb0450","first-page":"2253","article-title":"Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence","volume":"60","author":"Hoon","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0455","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1200\/JCO.2007.13.7653","article-title":"Impact of molecular staging methods in primary melanoma: reverse-transcriptase polymerase chain reaction (RT-PCR) of ultrasound-guided aspirate of the sentinel node does not improve diagnostic accuracy, but RT-PCR of peripheral blood does predict survival","volume":"26","author":"Voit","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0460","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bjd.12057","article-title":"Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression","volume":"168","author":"Reid","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0465","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nm.2753","article-title":"Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET","volume":"18","author":"Peinado","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0470","doi-asserted-by":"crossref","first-page":"828","DOI":"10.5858\/arpa.2013-0134-OA","article-title":"Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma","volume":"138","author":"Alegre","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0475","doi-asserted-by":"crossref","first-page":"e5219","DOI":"10.1371\/journal.pone.0005219","article-title":"High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients","volume":"4","author":"Logozzi","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2014.12.002_bb0480","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cca.2007.09.001","article-title":"Characterization of circulating DNA in healthy human plasma","volume":"387","author":"Suzuki","year":"2008","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2014.12.002_bb0485","first-page":"1659","article-title":"DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0490","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0495","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.cca.2011.07.027","article-title":"Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations","volume":"412","author":"Pinzani","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2014.12.002_bb0500","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","article-title":"Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA","volume":"20","author":"Oxnard","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0505","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1515\/CCLM.2006.260","article-title":"Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics","volume":"44","author":"Mitropapas","year":"2006","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0510","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/1078-0432.CCR-1169-3","article-title":"Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas","volume":"10","author":"Shinozaki","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0515","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1158\/0008-5472.CAN-06-0801","article-title":"Estrogen receptor-alpha methylation predicts melanoma progression","volume":"66","author":"Mori","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0520","doi-asserted-by":"crossref","first-page":"9351","DOI":"10.1200\/JCO.2005.02.9876","article-title":"Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy","volume":"23","author":"Mori","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0525","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/jid.2012.493","article-title":"Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma","volume":"133","author":"Lo Nigro","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0530","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.cca.2010.05.024","article-title":"Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients","volume":"411","author":"Pinzani","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2014.12.002_bb0535","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/sj.jid.5700073","article-title":"Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma","volume":"126","author":"Marini","year":"2006","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0540","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jnci\/djh011","article-title":"Circulating DNA microsatellites: molecular determinants of response to biochemotherapy in patients with metastatic melanoma","volume":"96","author":"Taback","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/bs.acc.2014.12.002_bb0545","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jdermsci.2010.12.010","article-title":"The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker","volume":"61","author":"Kanemaru","year":"2011","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/bs.acc.2014.12.002_bb0550","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1479-5876-10-155","article-title":"Serum microRNAs as biomarkers for recurrence in melanoma","volume":"10","author":"Friedman","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0555","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/CMR.0b013e328363e485","article-title":"Sensitive detection of melanoma metastasis using circulating microRNA expression profiles","volume":"23","author":"Shiiyama","year":"2013","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0560","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.28981","article-title":"Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients","volume":"1","author":"Fleming","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0565","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cca.2013.05.022","article-title":"Circulating cell free DNA: preanalytical considerations","volume":"424","author":"El Messaoudi","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2014.12.002_bb0570","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinbiochem.2009.08.027","article-title":"Is the role of circulating DNA as a biomarker of cancer being prematurely overrated?","volume":"43","author":"van der Vaart","year":"2010","journal-title":"Clin. Biochem."},{"key":"10.1016\/bs.acc.2014.12.002_bb0575","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/jnci\/dji432","article-title":"Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays","volume":"97","author":"Sozzi","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/bs.acc.2014.12.002_bb0580","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/clinchem\/44.10.2201","article-title":"Use of real-time quantitative PCR to compare DNA isolation methods","volume":"44","author":"de Kok","year":"1998","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2014.12.002_bb0585","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0590","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1373\/clinchem.2014.230235","article-title":"Quantitative cell-free circulating BRAFV600E mutation analysis using droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors","volume":"61","author":"Sanmamed","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2014.12.002_bb0595","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.canlet.2012.01.020","article-title":"Epigenetic biomarkers in skin cancer","volume":"342","author":"Greenberg","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/bs.acc.2014.12.002_bb0600","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0605","doi-asserted-by":"crossref","first-page":"e49843","DOI":"10.1371\/journal.pone.0049843","article-title":"Multiparametric analysis of cell-free DNA in melanoma patients","volume":"7","author":"Salvianti","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2014.12.002_bb0610","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1078-0432.CCR-06-2120","article-title":"Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy","volume":"13","author":"Shinozaki","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0615","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0620","doi-asserted-by":"crossref","first-page":"e30679","DOI":"10.1371\/journal.pone.0030679","article-title":"The majority of microRNAs detectable in serum and saliva is concentrated in exosomes","volume":"7","author":"Gallo","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2014.12.002_bb0625","doi-asserted-by":"crossref","first-page":"9136","DOI":"10.1073\/pnas.0508889103","article-title":"microRNAs exhibit high frequency genomic alterations in human cancer","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.acc.2014.12.002_bb0630","doi-asserted-by":"crossref","first-page":"14240","DOI":"10.3390\/ijms140714240","article-title":"Intercellular communication by exosome-derived microRNAs in cancer","volume":"14","author":"Hannafon","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.acc.2014.12.002_bb0635","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1038\/onc.2012.307","article-title":"microRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression","volume":"32","author":"Kappelmann","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/bs.acc.2014.12.002_bb0640","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.molimm.2013.11.018","article-title":"Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease","volume":"58","author":"Achberger","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0645","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.acc.2014.12.002_bb0650","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1046\/j.1365-2133.2000.03649.x","article-title":"Serological markers for melanoma","volume":"143","author":"Brochez","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0655","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ejca.2006.11.022","article-title":"Clinical value of combined determination of plasma l-DOPA\/tyrosine ratio, S100B, MIA and LDH in melanoma","volume":"43","author":"Garnier","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0660","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ejca.2011.08.007","article-title":"Comparative study of YKL-40, S-100B and LDH as monitoring tools for stage IV melanoma","volume":"48","author":"Egberts","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0665","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s13277-011-0218-x","article-title":"Evaluation of multiple serum markers in advanced melanoma","volume":"32","author":"Diaz-Lagares","year":"2011","journal-title":"Tumour Biol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0670","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cca.2013.11.034","article-title":"Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients","volume":"429","author":"Sanmamed","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2014.12.002_bb0675","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/cncr.25631","article-title":"Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma","volume":"117","author":"Eigentler","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0680","doi-asserted-by":"crossref","first-page":"e81624","DOI":"10.1371\/journal.pone.0081624","article-title":"Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy","volume":"8","author":"Weide","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2014.12.002_bb0685","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/jid.2012.36","article-title":"AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome","volume":"132","author":"Hoshimoto","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0690","doi-asserted-by":"crossref","first-page":"e89218","DOI":"10.1371\/journal.pone.0089218","article-title":"BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy","volume":"9","author":"Meckbach","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2014.12.002_bb0695","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/annonc\/mdt587","article-title":"Differential influence of vemurafenib and dabrafenib on patients\u2019 lymphocytes despite similar clinical efficacy in melanoma","volume":"25","author":"Schilling","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0700","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1148\/radiol.13130776","article-title":"Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab","volume":"270","author":"Gray","year":"2014","journal-title":"Radiology"},{"key":"10.1016\/bs.acc.2014.12.002_bb0705","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000351713","article-title":"Metastatic volume: an old oncologic concept and a new prognostic factor for stage IV melanoma patients","volume":"227","author":"Panasiti","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/bs.acc.2014.12.002_bb0710","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ijrobp.2012.06.009","article-title":"Karnofsky performance status and lactate dehydrogenase predict the benefit of palliative whole-brain irradiation in patients with advanced intra- and extracranial metastases from malignant melanoma","volume":"85","author":"Partl","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/bs.acc.2014.12.002_bb0715","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/bjc.2012.306","article-title":"Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis","volume":"107","author":"Weide","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0720","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/0973-1482.80458","article-title":"Can current prognostic scores reliably guide treatment decisions in patients with brain metastases from malignant melanoma?","volume":"7","author":"Nieder","year":"2011","journal-title":"J. Cancer Res. Ther."},{"key":"10.1016\/bs.acc.2014.12.002_bb0725","first-page":"1799","article-title":"Serum S100B and LDH are not useful in predicting the sentinel node status in melanoma patients","volume":"30","author":"Egberts","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/bs.acc.2014.12.002_bb0730","first-page":"449","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/bs.acc.2014.12.002_bb0735","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/COC.0b013e3181f9456a","article-title":"Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma","volume":"34","author":"Bedikian","year":"2011","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0740","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1245\/s10434-013-2949-y","article-title":"S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma","volume":"20","author":"Wevers","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0745","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.ejca.2010.04.023","article-title":"MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC","volume":"46","author":"Busch","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0750","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejso.2010.12.013","article-title":"The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection","volume":"37","author":"Kruijff","year":"2011","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0755","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ejca.2010.10.005","article-title":"Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952","volume":"47","author":"Bouwhuis","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0760","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/1471-2407-11-328","article-title":"Role of serum S100B and PET-CT in follow-up of patients with cutaneous melanoma","volume":"11","author":"Peric","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0765","first-page":"345","article-title":"The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1)","volume":"31","author":"Barak","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/bs.acc.2014.12.002_bb0770","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaad.2011.04.031","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"65","author":"Bichakjian","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0775","first-page":"578","article-title":"Serum S100B levels correlate with clinical benefit in a metastatic melanoma patient treated by CTLA-4 blockade: a case report","volume":"36","author":"Loquai","year":"2013","journal-title":"Onkologie"},{"key":"10.1016\/bs.acc.2014.12.002_bb0780","doi-asserted-by":"crossref","first-page":"843214","DOI":"10.1155\/2014\/843214","article-title":"Prognostic value of melanoma inhibitory activity protein in localized cutaneous malignant melanoma","volume":"2014","author":"Sandru","year":"2014","journal-title":"J. Skin Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0785","first-page":"880","article-title":"Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients","volume":"38","author":"Hofmann","year":"2011","journal-title":"J. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0790","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/CMR.0b013e32831bc78c","article-title":"Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma","volume":"19","author":"Hofmann","year":"2009","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0795","first-page":"513","article-title":"Elevation of a serum component in neoplastic disease","volume":"14","author":"Hill","year":"1954","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0800","first-page":"1114","article-title":"Usefulness of an elevated serum lactate dehydrogenase value as a marker of hepatic metastases in malignant melanoma","volume":"120","author":"Garg","year":"1979","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/bs.acc.2014.12.002_bb0805","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/1097-0142(19830301)51:5<840::AID-CNCR2820510516>3.0.CO;2-7","article-title":"LDH and melanoma","volume":"51","author":"Finck","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0810","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00008390-199604000-00013","article-title":"Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy","volume":"6","author":"Keilholz","year":"1996","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0815","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/bjc.1998.439","article-title":"Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma","volume":"78","author":"Franzke","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0820","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000099151","article-title":"S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests","volume":"28","author":"Missotten","year":"2007","journal-title":"Tumour Biol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0825","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.ejca.2009.04.016","article-title":"LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)","volume":"45","author":"Agarwala","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0830","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","article-title":"Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group","volume":"24","author":"Bedikian","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0835","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00008390-200302000-00008","article-title":"Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma","volume":"13","author":"Hamberg","year":"2003","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0840","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1158\/1078-0432.CCR-10-2402","article-title":"Plasma markers for identifying patients with metastatic melanoma","volume":"17","author":"Kluger","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0845","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s00726-012-1409-5","article-title":"Protein and non-protein biomarkers in melanoma: a critical update","volume":"43","author":"Tandler","year":"2012","journal-title":"Amino Acids"},{"key":"10.1016\/bs.acc.2014.12.002_bb0850","first-page":"89","article-title":"S100 protein family in human cancer","volume":"4","author":"Chen","year":"2014","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0855","first-page":"d1356","article-title":"S100 proteins: structure, functions and pathology","volume":"7","author":"Heizmann","year":"2002","journal-title":"Front. Biosci."},{"key":"10.1016\/bs.acc.2014.12.002_bb0860","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0361-9230(03)00089-3","article-title":"Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients","volume":"61","author":"Lamers","year":"2003","journal-title":"Brain Res. Bull."},{"key":"10.1016\/bs.acc.2014.12.002_bb0865","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1373\/clinchem.2013.212472","article-title":"Biomarkers of brain injury in cerebral infections","volume":"60","author":"Rohlwink","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2014.12.002_bb0870","doi-asserted-by":"crossref","first-page":"35037","DOI":"10.1074\/jbc.M104379200","article-title":"Inhibition of p53 transcriptional activity by the S100B calcium-binding protein","volume":"276","author":"Lin","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2014.12.002_bb0875","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4155\/fmc.12.191","article-title":"The evolution of S100B inhibitors for the treatment of malignant melanoma","volume":"5","author":"Hartman","year":"2013","journal-title":"Future Med. Chem."},{"key":"10.1016\/bs.acc.2014.12.002_bb0880","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ijc.1504","article-title":"On the release and half-life of S100B protein in the peripheral blood of melanoma patients","volume":"94","author":"Ghanem","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0885","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1472-6890-8-9","article-title":"Serum S100B levels after meningioma surgery: a comparison of two laboratory assays","volume":"8","author":"Einav","year":"2008","journal-title":"BMC Clin. Pathol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0890","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/bio.2461","article-title":"Development of a rapid and high-performance chemiluminescence immunoassay based on magnetic particles for protein S100B in human serum","volume":"28","author":"Zhang","year":"2013","journal-title":"Luminescence"},{"key":"10.1016\/bs.acc.2014.12.002_bb0895","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/abio.1997.2357","article-title":"Calcium-modulated proteins change their immunoreactivity in the presence of Ca2+: a study of antibody recognition in a dot immunoassay for calmodulin, calcineurin (beta-subunit), and S100B","volume":"253","author":"Goncalves","year":"1997","journal-title":"Anal. Biochem."},{"key":"10.1016\/bs.acc.2014.12.002_bb0900","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1515\/CCLM.2006.211","article-title":"Analysis of protein S-100B in serum: a methodological study","volume":"44","author":"Muller","year":"2006","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb0905","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.cca.2011.07.020","article-title":"Comparison of three assays for quantifying S-100B in serum","volume":"412","author":"Erickson","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/bs.acc.2014.12.002_bb0910","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/bjc.1998.368","article-title":"The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma","volume":"77","author":"Bonfrer","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0915","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1200\/JCO.2001.19.3.824","article-title":"Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma","volume":"19","author":"Martenson","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0920","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1365-2133.1997.18531946.x","article-title":"Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma","volume":"137","author":"Abraha","year":"1997","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb0925","first-page":"1897","article-title":"Serum markers to detect metastatic uveal melanoma","volume":"27","author":"Barak","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/bs.acc.2014.12.002_bb0930","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00008390-199710000-00005","article-title":"S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma","volume":"7","author":"Karnell","year":"1997","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0935","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000011989","article-title":"S100B protein detection in serum is a significant prognostic factor in metastatic melanoma","volume":"56","author":"Hauschild","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/bs.acc.2014.12.002_bb0940","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/ijc.23794","article-title":"The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis","volume":"123","author":"Mocellin","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb0945","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000135492","article-title":"Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH","volume":"31","author":"Egberts","year":"2008","journal-title":"Onkologie"},{"key":"10.1016\/bs.acc.2014.12.002_bb0950","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/CMR.0b013e328315c690","article-title":"Serological and immunohistochemical analysis of S100 and new derivatives as markers for prognosis in patients with malignant melanoma","volume":"18","author":"Bolander","year":"2008","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0955","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/CMR.0b013e3283650741","article-title":"S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma","volume":"23","author":"Abusaif","year":"2013","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0960","first-page":"5358","article-title":"Autocrine tumor cell growth-inhibiting activities from human malignant melanoma","volume":"49","author":"Bogdahn","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0965","first-page":"6237","article-title":"Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display","volume":"55","author":"van Groningen","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0970","first-page":"3149","article-title":"Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma","volume":"57","author":"Bosserhoff","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0975","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00008390-200108000-00013","article-title":"Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo","volume":"11","author":"Bosserhoff","year":"2001","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb0980","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/01.LAB.0000097191.12477.5D","article-title":"Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity","volume":"83","author":"Bosserhoff","year":"2003","journal-title":"Lab. Invest."},{"key":"10.1016\/bs.acc.2014.12.002_bb0985","doi-asserted-by":"crossref","first-page":"11669","DOI":"10.1074\/jbc.M511367200","article-title":"Regulation of integrin activity by MIA","volume":"281","author":"Bauer","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2014.12.002_bb0990","doi-asserted-by":"crossref","first-page":"e37941","DOI":"10.1371\/journal.pone.0037941","article-title":"Targeting melanoma metastasis and immunosuppression with a new mode of melanoma inhibitory activity (MIA) protein inhibition","volume":"7","author":"Schmidt","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2014.12.002_bb0995","first-page":"5041","article-title":"MIA as a reliable tumor marker in the serum of patients with malignant melanoma","volume":"20","author":"Stahlecker","year":"2000","journal-title":"Anticancer Res"},{"key":"10.1016\/bs.acc.2014.12.002_bb1000","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00008390-200112000-00009","article-title":"Prognostic significance of melanoma inhibiting activity levels in malignant melanoma","volume":"11","author":"Meral","year":"2001","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb1005","first-page":"981","article-title":"Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma","volume":"9","author":"Guba","year":"2002","journal-title":"Oncol. Rep."},{"key":"10.1016\/bs.acc.2014.12.002_bb1010","first-page":"1311","article-title":"S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase","volume":"21","author":"Krahn","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/bs.acc.2014.12.002_bb1015","first-page":"595","article-title":"Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma","volume":"27","author":"Cao","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/bs.acc.2014.12.002_bb1020","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0140-6736(00)02486-7","article-title":"Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma","volume":"356","author":"Wagner","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/bs.acc.2014.12.002_bb1025","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/rheumatology\/38.2.148","article-title":"MIA (melanoma inhibitory activity): a potential serum marker for rheumatoid arthritis","volume":"38","author":"Muller-Ladner","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/bs.acc.2014.12.002_bb1030","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1365-2230.2004.01623.x","article-title":"Elevated MIA levels in the serum of pregnant women and of children","volume":"29","author":"Bosserhoff","year":"2004","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb1035","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1074\/jbc.271.6.3311","article-title":"Cloning of a retinoic acid-sensitive mRNA expressed in cartilage and during chondrogenesis","volume":"271","author":"Dietz","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2014.12.002_bb1040","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3858\/emm.2010.42.3.017","article-title":"Modulation of cartilage differentiation by melanoma inhibiting activity\/cartilage-derived retinoic acid-sensitive protein (MIA\/CD-RAP)","volume":"42","author":"Schubert","year":"2010","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb1045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2013.11.002","article-title":"Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning","volume":"25","author":"Vempati","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/bs.acc.2014.12.002_bb1050","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s001099900019","article-title":"Molecular and biological properties of vascular endothelial growth factor","volume":"77","author":"Ferrara","year":"1999","journal-title":"J. Mol. Med."},{"key":"10.1016\/bs.acc.2014.12.002_bb1055","first-page":"852","article-title":"Angiogenesis and melanoma\u2014from basic science to clinical trials","volume":"1","author":"Emmett","year":"2011","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb1060","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/bjc.1997.486","article-title":"Enhanced expression of vascular endothelial growth factor in metastatic melanoma","volume":"76","author":"Salven","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb1065","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2133.2005.06507.x","article-title":"Circulating vascular endothelial growth factor in cutaneous malignant melanoma","volume":"152","author":"Pelletier","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb1070","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1200\/JCO.2001.19.2.577","article-title":"Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival","volume":"19","author":"Ugurel","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb1075","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/00008390-200208000-00004","article-title":"VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course","volume":"12","author":"Osella-Abate","year":"2002","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb1080","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-13-3203","article-title":"Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins","volume":"20","author":"Sanmamed","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb1085","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/1055-9965.EPI-05-0011","article-title":"Serum YKL-40, a new prognostic biomarker in cancer patients?","volume":"15","author":"Johansen","year":"2006","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/bs.acc.2014.12.002_bb1090","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2005.03.7960","article-title":"Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma","volume":"24","author":"Schmidt","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb1095","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0092-8674(94)90498-7","article-title":"Galectins: a family of animal beta-galactoside-binding lectins","volume":"76","author":"Barondes","year":"1994","journal-title":"Cell"},{"key":"10.1016\/bs.acc.2014.12.002_bb1100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10495-005-0801-y","article-title":"On the role of galectin-3 in cancer apoptosis","volume":"10","author":"Nakahara","year":"2005","journal-title":"Apoptosis"},{"key":"10.1016\/bs.acc.2014.12.002_bb1105","doi-asserted-by":"crossref","first-page":"e5199","DOI":"10.1371\/journal.pone.0005199","article-title":"Proteome serological determination of tumor-associated antigens in melanoma","volume":"4","author":"Forgber","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2014.12.002_bb1110","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/j.1468-3083.2010.03943.x","article-title":"Prognostic value of galectin-3 in primary cutaneous melanoma","volume":"25","author":"Buljan","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/bs.acc.2014.12.002_bb1115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2230.2005.01992.x","article-title":"High serum galectin-3 in advanced melanoma: preliminary results","volume":"31","author":"Vereecken","year":"2006","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb1120","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/CMR.0b013e32832ec001","article-title":"Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients","volume":"19","author":"Vereecken","year":"2009","journal-title":"Melanoma Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb1125","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1468-3083.2006.01853.x","article-title":"Is serum galectin-3 a potential predictor of the response to active specific immunotherapy in melanoma patients?","volume":"21","author":"Vereecken","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/bs.acc.2014.12.002_bb1130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/10408363.2012.677947","article-title":"The immunosuppressive molecule HLA-G and its clinical implications","volume":"49","author":"Gonzalez","year":"2012","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/bs.acc.2014.12.002_bb1135","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1399-0039.2006.763_5.x","article-title":"Quantification and identification of soluble HLA-G isoforms","volume":"69","author":"Rebmann","year":"2007","journal-title":"Tissue Antigens"},{"key":"10.1016\/bs.acc.2014.12.002_bb1140","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1097-0142(20010715)92:2<369::AID-CNCR1332>3.0.CO;2-U","article-title":"Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy","volume":"92","author":"Ugurel","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/bs.acc.2014.12.002_bb1145","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1158\/1078-0432.CCR-12-3697","article-title":"Molecular pathways: human leukocyte antigen G (HLA-G)","volume":"19","author":"Curigliano","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.acc.2014.12.002_bb1150","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.clinbiochem.2012.12.011","article-title":"The contribution of proteomics to the identification of biomarkers for cutaneous malignant melanoma","volume":"46","author":"Bougnoux","year":"2012","journal-title":"Clin. Biochem."},{"key":"10.1016\/bs.acc.2014.12.002_bb1155","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1196\/annals.1318.047","article-title":"Detection of differentially expressed proteins in early stage melanoma patients using SELDI-TOF mass spectrometry","volume":"1022","author":"Wilson","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/bs.acc.2014.12.002_bb1160","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1200\/JCO.2008.18.0554","article-title":"Serum amyloid a as a prognostic marker in melanoma identified by proteomic profiling","volume":"27","author":"Findeisen","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb1165","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":"Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma","volume":"19","author":"Balch","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 7","key":"10.1016\/bs.acc.2014.12.002_bb1170","doi-asserted-by":"crossref","first-page":"vii86","DOI":"10.1093\/annonc\/mds229","article-title":"Cutaneous7: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Dummer","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.acc.2014.12.002_bb1175","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2010.09883.x","article-title":"Revised U.K. guidelines for the management of cutaneous melanoma 2010","volume":"163","author":"Marsden","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/bs.acc.2014.12.002_bb1180","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000081482","article-title":"Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma","volume":"210","author":"Dummer","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/bs.acc.2014.12.002_bb1185","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/CMR.0b013e328347105e","article-title":"Receiver operating characteristic analysis: calculation for the marker \u2018melanoma inhibitory activity\u2019 in metastatic uveal melanoma patients","volume":"21","author":"Klingenstein","year":"2011","journal-title":"Melanoma Res."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242314000419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242314000419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:33:05Z","timestamp":1758742385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242314000419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9780128022658"],"references-count":237,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2014.12.002","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}